Article (Scientific journals)
Anaemia and cancer : oral or intravenous iron ?
Aapro, Matti S.; Österborg, Anders; Gascon, Pere et al.
2012In Therapeutics, p. 46-48
Peer reviewed
 

Files


Full Text
288.pdf
Publisher postprint (389.15 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
iron; anaemia; chemotherapy-induced anaemia; intravenous iron; hepcidin
Abstract :
[en] Anaemia and absolute or functional iron deficiency (ID) are common issues among cancer patients, with the prevalence of ID ranging from 32% to 60%. Most randomised clinical trials have shown superior efficacy of IV iron over oral or no iron supplementation in anaemic cancer patients receiving erythropoiesis-stimulating agents. Intravenous iron supplementation reduced blood transfusions, increased haemoglobin, and improved quality of life. At recommended doses, IV iron is well tolerated, and allergic reactions are exceedingly rare with modern formulations. Oral iron is often poorly tolerated and this can lead to compliance issues.
Disciplines :
Hematology
Author, co-author :
Aapro, Matti S.
Österborg, Anders
Gascon, Pere
Ludwig, Heinz
Beguin, Yves  ;  Université de Liège - ULiège > GIGA-R : Hématologie
Language :
English
Title :
Anaemia and cancer : oral or intravenous iron ?
Publication date :
2012
Journal title :
Therapeutics
Pages :
46-48
Peer reviewed :
Peer reviewed
Available on ORBi :
since 11 July 2013

Statistics


Number of views
120 (3 by ULiège)
Number of downloads
542 (1 by ULiège)

Bibliography


Similar publications



Contact ORBi